Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain
Aim: To estimate the cost-effectiveness of treating postmenopausal osteoporosis (PMO) with weekly gastro-resistant risedronate 35 mg gastro-resistant tablets (RIS-GR), compared with weekly alendronate 70 mg tablets (ALN) in Spain. Methods: A probabilistic analysis (second-orderMonte Carlo simulation...
Saved in:
Main Authors: | Enrique Casado (Author), Jose Rosas (Author), Carlos Rubio-Terres (Author), Dario Rubio-Rodriguez (Author), Mitra Boolell (Author), Ignacio Aristegui (Author) |
---|---|
Format: | Book |
Published: |
Becaris Publishing Limited,
2023-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Effects of Once-Weekly Alendronate 70 mg, Risedronate 35 mg and Raloxifene 60 mg Daily in the Treatment of Postmenopausal Osteoporosis in Turkish Population
by: Mesut Öktem, et al.
Published: (2007) -
The Effect of Once-Weekly 70 Mg Alendronate Versus Once-Daily 10 Mg Alendronate in the Treatment of Postmenopausal Osteoporosis
by: İlker Çorapçı, et al.
Published: (2004) -
First Indian prospective randomized comparative study evaluating adherence and compliance of postmenopausal osteoporotic patients for daily alendronate, weekly risedronate and monthly ibandronate regimens of bisphosphonates
by: Vishal R Tandon, et al.
Published: (2014) -
Bioequivalence of generic alendronate sodium tablets (70 mg) to Fosamax® tablets (70 mg) in fasting, healthy volunteers: a randomized, open-label, three-way, reference-replicated crossover study
by: Zhang Y, et al.
Published: (2017) -
Once-monthly risedronate for postmenopausal osteoporosis
by: Kristina Casadei, et al.
Published: (2009)